Year in Review 2024: Updates in the Management of Advanced EGFR-Mutant NSCLC

Sandip P. Patel, MD; Zofia Piotrowska, MD, MHS; and Joel Neal, MD, PhD, discuss how the evolving landscape of EGFR-mutated non–small cell lung cancer treatment now includes 3 compelling frontline options (osimertinib monotherapy, FLAURA2 regimen, and MARIPOSA), requiring careful consideration of patient factors, disease characteristics, and toxicity profiles for optimal treatment selection and sequencing strategies.

x